# Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/) · 2026-11-16 · Medicine
Page: https://themorning.science/story/summit-shares-fall-as-fda-rejects-closely-watched-pd-1-vegf-drug-a8b2d96606b4d882
Kind: business · Impact: medium

## In brief

- The FDA rejected ivonescimab, a PD-1/VEGF drug from Summit and Akeso, for a form of lung cancer.
- The FDA refused to overlook the drug's failure to initially extend survival in that lung cancer population.
- Summit shares fell, and the decision sets back Summit's first chance to win a U.S. approval.

## Why it matters

The rejection shows that the FDA will not overlook a failure to show an initial survival benefit, even for a closely watched new class of cancer drug, which matters for how science readers judge the strength of trial evidence in oncology.

## Timeline

- 2026-11-16: FDA rejects ivonescimab for a form of lung cancer, and Summit shares fall

## Coverage

- [Summit shares fall as FDA rejects closely watched PD-1/VEGF drug](https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/) — BioPharma Dive - Latest News, 2026-11-16

Tags: ivonescimab, pd-1/vegf, lung cancer, fda, drug approval, biotech

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
